Evaluating the Efficacy and Safety of Treatments for VMS During Adjuvant Endocrine Therapy
A panelist highlights that new nonhormonal treatments show promising, well-tolerated relief of persistent vasomotor symptoms (VMS) in patients with hormone receptor–positive breast cancer receiving endocrine therapy, improving quality of life and adherence while ongoing research addresses long-term safety and underserved populations.
EP. 1: Lead Investigator Insights on Adjuvant Endocrine Therapy Landscape
June 13th 2025A panelist discusses how endocrine therapy remains the cornerstone of treatment for hormone receptor–positive, HER2-negative breast cancer, emphasizing its role in reducing relapse risk and mortality while highlighting the importance of tolerability and individualized care across the subtype’s heterogeneous presentations.
EP. 2: Navigating Vasomotor Symptoms From Endocrine Therapy in Breast Cancer Treatment
June 13th 2025A panelist notes that although chemotherapy’s adverse effects are intense but short-lived, endocrine therapy for hormone receptor–positive breast cancer involves persistent symptoms over several years, making symptom management essential for patient adherence and quality of life.
